Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07221838 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab

Study acronym: OCTAGON
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Start date changed from estimate of Feb 27, 2026 to Mar 4, 2026 · Site details revised at 12 of 12 sitesv8 Show 2 more changesShow less
    • Start date changed from estimate of Feb 27, 2026 to Mar 4, 2026
    • Site details revised at 12 of 12 sites
  2. Study sites: 13 to 12v7
  3. Study sites: 11 to 13v6
  4. Study sites: 15 to 11v5
  5. Start date: Dec 31, 2025 to Feb 27, 2026 Primary and study completion dates: Jun 30, 2027 to Aug 27, 2027v4 Show 1 more changeShow less
    • Primary and study completion dates: Jun 30, 2027 to Aug 27, 2027
Show 2 earlier versionsHide 2 earlier versions
  1. Study sites: 14 to 15v3
  2. Study sites: 0 to 14v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AstraZeneca
727 trials monitored
See 61 trials at risk
Myasthenia Gravis
187 trials monitored
See 7 trials at risk
This is a prospective, multicenter single arm study designed to evaluate the effectiveness and safety of a predefined oral corticosteroids (OCS) tapering schedule to reduce OCS use in adult participants with acetylcholine receptor positive (AChR+) generalized myasthenia gravis (gMG) being treated with intravenous ravulizumab.
Trial Details
NCT Number NCT07221838
Lead Sponsor Alexion Pharmaceuticals, Inc.
Conditions Generalized Myasthenia Gravis, gMG
Enrollment 75 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov